Filing of a Counterclaim in Response to the Lawsuit Against Us
Filing company (HEALIOS K.K.)
Method for manufacturing conditioned medium for technology transfer to conditioned medium and CPC
AND medical group failed to pay the ¥60 million final milestone payment under the joint research agreement after the payment deadline of 31 May 2025 had passed.
Related procedures
Counterclaim
Tokyo District Court
HEALIOS K.K. (counterclaim plaintiff)
General Incorporated Association AND medical group (counterclaim defendant)
¥66,000,000 plus damages for delay (at an annual rate of 3%)
We will continue responding to this lawsuit and promptly disclose any matters requiring disclosure, including any impact on financial results.
We will promptly disclose any matters requiring disclosure, including any impact on financial results.
| Item | Details |
|---|---|
| Event name | Filing of a Counterclaim in Response to the Lawsuit Against Us |
| Date of occurrence | 9 June 2026 (date the counterclaim was filed) |
| Subject Entity | Filing company (HEALIOS K.K.) |
| Target Locations / Products | Method for manufacturing conditioned medium for technology transfer to conditioned medium and CPC |
| Cause | AND medical group failed to pay the ¥60 million final milestone payment under the joint research agreement after the payment deadline of 31 May 2025 had passed. |
| Type of litigation or proceeding | Counterclaim |
| Court or authority | Tokyo District Court |
| Plaintiff | HEALIOS K.K. (counterclaim plaintiff) |
| Defendant | General Incorporated Association AND medical group (counterclaim defendant) |
| Date of filing / date of action | 9 June 2026 |
| Claim amount / surcharge amount | ¥66,000,000 plus damages for delay (at an annual rate of 3%) |
| Outlook | We will continue responding to this lawsuit and promptly disclose any matters requiring disclosure, including any impact on financial results. |
| Planned follow-up disclosure | We will promptly disclose any matters requiring disclosure, including any impact on financial results. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.AND medical group failed to pay the ¥60 million final milestone payment stipulated in the joint research agreement by the payment deadline of 31 May 2025.